Biotech Startups

Atlas Antibodies develops and supplies validated antibodies and reagents for life-science research, building on work from the Human Protein Atlas project. Its offerings target researchers running protein-detection experiments across tissues, with a focus on validation rigor and application support.

1 investor

Atlas Clinical operates as a clinical research site conducting FDA-regulated trials for pharmaceutical and biotechnology sponsors. The company recruits and manages volunteer participants through multi-phase in-human testing of new drug candidates and therapeutic devices.

1 investor

AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.

1 investor

Atlas Venture is a venture capital firm that invests in life sciences and biotech companies, with a team of advisors and entrepreneurs-in-residence who are experienced leaders in drug discovery and therapeutics development.

1 investor

AtlasXomics develops spatial epigenomics tools, spanning chip fabrication, hardware, and bioinformatics, for researchers studying areas such as cancer and systems biology. The company serves scientific and clinical research customers with technology for analyzing epigenetic regulation.

1 investor

Atmo Biosciences develops an FDA-cleared ingestible capsule using gas-sensing technology to diagnose gastrointestinal dysmotility conditions for gastroenterologists. The product provides objective clinical data to help manage treatment decisions and side effects in patients, particularly those experiencing gastrointestinal complications from GLP-1 weight loss medications.

1 investor

AtomVie is a contract development and manufacturing organization (CDMO) that provides cGMP manufacturing and global distribution of radiopharmaceuticals for diagnostic and therapeutic applications. The company serves clinical developers and commercial manufacturers advancing drugs through development toward commercialization.

1 investor

Atransen Pharma is a biotech company developing novel cancer treatments through LAT1 inhibitors and transporter-based drug discovery approaches. The company's research builds on amino acid transporter science from Osaka University and aims to create more effective cancer therapies with fewer side effects.

1 investor

ATRO Medical is a Dutch clinical-stage orthopedic company developing the Artimis artificial meniscus implant (prosthesis) for patients with chronic knee pain after meniscectomy. Its device is being evaluated in clinical trials at Dutch hospitals and has received FDA breakthrough device designation.

1 investor

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss. The company focuses on genetic medicines for conditions with limited approved therapies, utilizing proprietary AAV technology platforms.

1 investor

AuB develops gut microbiome research-backed healthcare products and services, primarily targeting athletes and the sports community. The company combines athlete microbiome data and AI analysis to create conditioning and health products aimed at optimizing personal performance and wellbeing.

1 investor

Audaxis Medical develops biocompatible pelvic health implants using next-generation biomaterials designed to integrate with the body and replace legacy materials. The company focuses on women's pelvic health solutions that prioritize safety, durability, and clinical efficacy.

1 investor

1 investor

Augurex develops and commercializes diagnostic tests for autoimmune conditions, with a focus on reducing diagnostic delays and enabling timely patient care. The company's offerings include tests for rheumatoid arthritis and axial spondyloarthritis.

1 investor

August Bioservices is a contract research, development, and manufacturing organization (CDMO) specializing in sterile injectables, offering end-to-end services from development to commercial manufacturing. It serves pharmaceutical and biotech companies developing novel therapeutics.

1 investor

Aukera Therapeutics is a preclinical-stage biotech company, spun out of the University of Basel's Biozentrum, developing the first RAPTOR inhibitors to treat mTORC1-related diseases. It pairs mTOR pathway expertise with an AI-driven drug discovery engine aimed at complex, hard-to-drug targets.

1 investor

Auni Therapeutics develops immunotherapy treatments for food allergies, leveraging intralymphatic immunotherapy (ILIT) protocols and proprietary clinical innovations. The company serves patients with allergic disease and aims to bring next-generation allergen immunotherapies to market.

1 investor

Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.

1 investor

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.

1 investor

Auristone builds an epigenomic database focused on Asian cohorts and diseases to enable drug and biomarker discoveries. The company develops proprietary predictive models based on epigenomics data across cancer types to provide clinical insights that complement genomic information.

1 investor

1 investor

Aurora develops a platform for personalized gene editing to treat rare genetic diseases at scale. The company targets patients with rare disease variants by systematizing and scaling gene editing treatments to address genetic mutations that lack existing therapeutic options.

1 investor

AusBiotech is the national industry association representing Australia's life sciences ecosystem, advocating for policy, facilitating connections, and supporting growth for biotechnology, medical technologies, and digital health companies.

1 investor

AusperBio is a Phase II clinical-stage biopharmaceutical company developing oligonucleotide (ASO) therapeutics, with a focus on curative treatments for hepatitis B (HBV). It uses a proprietary Med-Oligo ASO platform and targeted delivery technologies to address viral infections, metabolic, genetic, and immune diseases.

1 investor